NO20016121L - Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 - Google Patents

Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1

Info

Publication number
NO20016121L
NO20016121L NO20016121A NO20016121A NO20016121L NO 20016121 L NO20016121 L NO 20016121L NO 20016121 A NO20016121 A NO 20016121A NO 20016121 A NO20016121 A NO 20016121A NO 20016121 L NO20016121 L NO 20016121L
Authority
NO
Norway
Prior art keywords
methods
abc
relates
polypeptides
well
Prior art date
Application number
NO20016121A
Other languages
English (en)
Norwegian (no)
Other versions
NO20016121D0 (no
Inventor
Richard Mark Lawn
David Wade
John F Oram
Michael Garvin
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of NO20016121D0 publication Critical patent/NO20016121D0/no
Publication of NO20016121L publication Critical patent/NO20016121L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
NO20016121A 1999-06-18 2001-12-14 Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 NO20016121L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14026499P 1999-06-18 1999-06-18
US15387299P 1999-09-14 1999-09-14
US16657399P 1999-11-19 1999-11-19
PCT/US2000/016591 WO2000078971A2 (fr) 1999-06-18 2000-06-16 Compositions et procedes visant a augmenter la sortie de cholesterol et a augmenter la hdl au moyen de la proteine de transport de cassettes de liaison d'atp abc1

Publications (2)

Publication Number Publication Date
NO20016121D0 NO20016121D0 (no) 2001-12-14
NO20016121L true NO20016121L (no) 2002-02-12

Family

ID=27385472

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20016121A NO20016121L (no) 1999-06-18 2001-12-14 Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1
NO20016114A NO20016114L (no) 1999-06-18 2001-12-14 Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20016114A NO20016114L (no) 1999-06-18 2001-12-14 Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1

Country Status (19)

Country Link
EP (2) EP1218515B1 (fr)
JP (4) JP2003506097A (fr)
KR (2) KR100476519B1 (fr)
CN (2) CN100513570C (fr)
AR (2) AR024391A1 (fr)
AT (1) ATE422545T1 (fr)
AU (3) AU777461B2 (fr)
BR (2) BR0011753A (fr)
CA (2) CA2375787C (fr)
DE (1) DE60041545D1 (fr)
HK (2) HK1046427A1 (fr)
IL (2) IL147022A0 (fr)
MX (2) MXPA01013175A (fr)
NO (2) NO20016121L (fr)
NZ (3) NZ531401A (fr)
SG (2) SG121853A1 (fr)
TR (2) TR200200441T2 (fr)
TW (2) TWI259205B (fr)
WO (2) WO2000078971A2 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
EP1854880A1 (fr) * 1999-03-15 2007-11-14 University of British Columbia Procédés et réactifs pour moduler les niveaux de cholestérol
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
CA2382562A1 (fr) * 1999-09-01 2001-03-08 University Of British Columbia Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides
US6555323B2 (en) * 2000-02-08 2003-04-29 Pfizer Inc. Assay for ABCA1
MXPA02010684A (es) 2000-05-02 2003-03-10 Aventis Pharma Sa Secuencias de acido nucleico regulador del gen abc1.
EP1203588A1 (fr) * 2000-11-06 2002-05-08 Bayer Ag Régulation stérol-indépendante du promoteur ABC1 par l' oncostatineM
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2003004692A2 (fr) * 2001-07-03 2003-01-16 Xenon Genetics, Inc. Procedes de criblage d'agents modulant les taux de cholesterol
CA2463395A1 (fr) * 2001-10-12 2003-04-24 Grelan Pharmaceutical Co., Ltd. Agents therapeutiques pour l'hypocholesterolemie hdl
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
EP1465869B1 (fr) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulateurs de lxr
ES2367539T3 (es) 2001-12-21 2011-11-04 X-Ceptor Therapeutics, Inc. Moduladores heterocíclicos de receptores nucleares.
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2004058717A1 (fr) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Derives d'isoquinolinone et leur utilisation comme agents therapeutiques
US8466143B2 (en) 2003-07-23 2013-06-18 Exelixis, Inc. Azepine derivatives as pharmaceutical agents
WO2005116057A1 (fr) * 2004-05-27 2005-12-08 Baker Medical Research Institute Anticorps monoclonal dirigé contre le gène abca1
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US8119686B2 (en) 2006-11-24 2012-02-21 Hykes Laboratories Llc Spiroquinone compound and pharmaceutical composition
CA2673331A1 (fr) 2006-12-19 2008-06-26 Ablynx N.V. Sequences d'acides amines dirigees contre les gpcr et polypeptides les contenant pour le traitement de maladies et de troubles lies au gpcr
EP2102244A2 (fr) 2006-12-19 2009-09-23 Ablynx N.V. Séquences d'acides aminés dirigées contre une métalloprotéinase de la famille adam et polypeptides les comprenant à des fins de traitement de maladies et troubles liés à adam
EP2650311A3 (fr) 2007-11-27 2014-06-04 Ablynx N.V. Séquences d'acides aminés dirigées contre des cytokines hétérodimériques et/ou leurs récepteurs et polypeptides les comprenant
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2414521B1 (fr) * 2009-03-31 2016-10-26 The General Hospital Corporation Régulation des microarn mir-33 dans le traitement des troubles liés au cholestérol
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
KR101676704B1 (ko) 2009-05-28 2016-11-16 엑셀리시스 페이턴트 컴퍼니 엘엘씨 Ｌｘｒ 조절자
WO2011045079A1 (fr) 2009-10-15 2011-04-21 Intercell Ag Anticorps humains spécifiques du virus de l'hépatite b
AU2011328246B2 (en) 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
EP2723772A1 (fr) 2011-06-23 2014-04-30 Ablynx N.V. Domaines variables uniques d'immunoglobuline dirigés contre ige
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CN104619350A (zh) 2012-06-14 2015-05-13 Ambrx公司 结合到核受体配体多肽的抗psma抗体
US9101745B2 (en) * 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
JP6456909B2 (ja) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
CN105209039B (zh) 2013-03-15 2018-06-22 百时美施贵宝公司 Lxr调节剂
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
GB201315136D0 (en) * 2013-08-23 2013-10-09 Univ Glasgow Cholesterol modulation
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
KR20180080337A (ko) 2015-11-27 2018-07-11 아블린쓰 엔.브이. Ｃｄ40ｌ을 억제하는 폴리펩티드
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
BR112019010061A2 (pt) 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
TW202417517A (zh) 2017-06-02 2024-05-01 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
CN118894939A (zh) 2017-06-02 2024-11-05 默克专利股份有限公司 结合adamts的免疫球蛋白
NZ759601A (en) 2017-06-02 2023-06-30 Merck Patent Gmbh Aggrecan binding immunoglobulins
JP7249961B2 (ja) 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
IL296251A (en) * 2020-03-06 2022-11-01 Endolytix Tech Inc Compositions and methods for the treatment of intracellular bacterial infections
CN115433733B (zh) 2021-06-04 2025-12-12 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
CN114369162B (zh) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
CA3262070A1 (fr) 2022-07-14 2025-06-13 Bio-Thera Solutions, Ltd. Anticorps anti-nectine-4 et son utilisation
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
EP4731770A1 (fr) 2023-06-22 2026-04-29 Ablynx NV Protéines chimériques pour moduler l'activité d'un récepteur de cytokine
CN118027196B (zh) 2023-06-25 2025-12-02 合肥天港免疫药物有限公司 抗cd3抗体及其应用
WO2025008537A1 (fr) 2023-07-05 2025-01-09 Ablynx Nv Antagonistes de fcrn améliorés pour le traitement de maladies et de troubles liés à l'igg
WO2025051767A1 (fr) 2023-09-04 2025-03-13 Sanofi Polypeptides à utiliser dans le traitement de tumeurs exprimant le glypicane-3
CN119569886A (zh) 2023-09-06 2025-03-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2025056575A1 (fr) 2023-09-11 2025-03-20 Novo Nordisk A/S Anticorps anti-domaine il-6
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
TW202543670A (zh) 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 用於核內投予之基於蛋白質的接合載劑
TW202542180A (zh) 2023-12-22 2025-11-01 比利時商艾伯霖克斯公司 用於位點特異性胺軛合的基於蛋白質的載體
WO2025207946A1 (fr) 2024-03-28 2025-10-02 Genzyme Corporation Polypeptides se liant à un épitope spécifique du récepteur 1 de la transferrine
US20260007757A1 (en) 2024-06-18 2026-01-08 Ablynx Nv Antibody-recruiting molecules
WO2026078159A1 (fr) 2024-10-10 2026-04-16 Ablynx Nv Agents d'activation de cellules immunitaires et procédés les comprenant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010684A (es) * 2000-05-02 2003-03-10 Aventis Pharma Sa Secuencias de acido nucleico regulador del gen abc1.

Also Published As

Publication number Publication date
WO2000078972A8 (fr) 2001-06-21
EP1218515A2 (fr) 2002-07-03
KR100476519B1 (ko) 2005-03-17
BR0011753A (pt) 2002-04-30
CA2375781A1 (fr) 2000-12-28
CN100513570C (zh) 2009-07-15
NZ516061A (en) 2004-04-30
NZ529785A (en) 2005-09-30
JP2003506097A (ja) 2003-02-18
WO2000078971A2 (fr) 2000-12-28
TWI304737B (en) 2009-01-01
IL147022A0 (en) 2002-08-14
JP4277956B2 (ja) 2009-06-10
NO20016114D0 (no) 2001-12-14
KR20020012612A (ko) 2002-02-16
SG121852A1 (en) 2006-05-26
SG121853A1 (en) 2006-05-26
WO2000078972A9 (fr) 2002-07-18
KR20020012281A (ko) 2002-02-15
AU777461B2 (en) 2004-10-14
WO2000078972A2 (fr) 2000-12-28
AU5743400A (en) 2001-01-09
AU2005200171A1 (en) 2005-02-10
NZ531401A (en) 2005-08-26
JP2003508031A (ja) 2003-03-04
NO20016121D0 (no) 2001-12-14
TW200626176A (en) 2006-08-01
WO2000078971A3 (fr) 2002-01-17
TR200200441T2 (tr) 2002-11-21
TR200200440T2 (tr) 2002-09-23
MXPA01013174A (es) 2002-06-04
CA2375787C (fr) 2007-03-27
BR0011696A (pt) 2002-04-30
HK1046708A1 (zh) 2003-01-24
EP1218515B1 (fr) 2009-02-11
NO20016114L (no) 2002-02-12
CN1434865A (zh) 2003-08-06
ATE422545T1 (de) 2009-02-15
JP2005112859A (ja) 2005-04-28
CA2375787A1 (fr) 2000-12-28
HK1046427A1 (zh) 2003-01-10
AR024576A1 (es) 2002-10-16
JP2006137750A (ja) 2006-06-01
EP1190065A2 (fr) 2002-03-27
AR024391A1 (es) 2002-10-02
CN1379817A (zh) 2002-11-13
DE60041545D1 (de) 2009-03-26
MXPA01013175A (es) 2002-06-04
AU5746700A (en) 2001-01-09
TWI259205B (en) 2006-08-01
IL147021A0 (en) 2002-08-14
WO2000078972A3 (fr) 2002-05-02

Similar Documents

Publication Publication Date Title
NO20016121L (no) Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1
Sebastiano et al. A new deuterated alkylating agent for quantitative proteomics
DK1012274T4 (da) Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
ATE352618T1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
DK1032660T3 (da) Fremgangsmåde til identivicering af bindingsstedsdominans som bevarer evnen til at binde til en epitop
DK0981618T3 (da) Anti-Apo-2-antistof
NO20060236L (no) Antistoffer spesifikke for sklerostinro og fremgangsmate for a oke benmineralisering
CA2063822A1 (fr) Methode de modulation de l'expression genique par la transcription et de decouverte de substances chimiques pouvant servir de modulateurs de l'expression genique
AU1155395A (en) Retinoid receptor compositions, antibodies and methods
DE60234131D1 (de) Neue fusionsproteine und molekulare bindungsassays
EP1454992B1 (fr) Essai de kinase lymphome anaplastique, ses réactifs et compositions
CA2148252A1 (fr) Systeme de piegeage pour l'isolement de nouvelles proteines
DK0576623T4 (da) Bindingsdomæner i Notch-proteiner
DK1005488T4 (da) Receptor som binder TRAIL
WO1999043808A8 (fr) Compositions de c-maf humaine et leurs methodes d'utilisation
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
Hochrein et al. An examination of dynamics crosstalk between SH2 and SH3 domains by hydrogen/deuterium exchange and mass spectrometry
NO962084L (no) DNA sekvens som koder for en BMP reseptor
WO1999047686A3 (fr) Proteines humaines mekk, molecules d'acides nucleiques et procedes d'utilisation correspondants
EP1178828A4 (fr) Recepteur 4 contenant le domaine de la mort cellulaire programmee
Trimmer et al. 36 Phosphorylation of voltage-gated ion channels
ATE308615T1 (de) T-bet zusammensetzungen und deren vervendungsmethoden
WO2002087606A3 (fr) Modulateurs du systeme de l'hypocretine et methodes de criblage associees
NO983984L (no) Disintegrin-metalloprotease samt anvendelse derav
WO2002004601A3 (fr) Proteines mammiferes se liant a mdm2 et leurs applications

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application